(Total Views: 714)
Posted On: 01/06/2022 8:03:46 PM
Post# of 153984
Of note:
Trodelvy consists of two drugs. One targets and downregulates Trop-2 which is involved in CA-2+ signaling. Leronlomab downregulates CA-2+ itself.
The other drug is SN-38 that downregulates topoisomerase I. Topoisomerase I is implicated in tumor cellular repair. Leronlimab stops tumor cellular repair through the PI-3K/AKT pathway.
Now add leronlimab's other tumor fighting abilities - inhibits angiogenesis, anti-trafficking of tumor cells, increase in tumor fighting NKT cells, Stops the recruitment of Tregs to tumor sites (Tregs promote tumor immunity), downregulates IL-13 a tumor protectant, IL-4 (IL-4 promotes tumor immunity), upregulates IFN-gamma promoting tumor cell death and downregulates PD-L1.
Trodelvy consists of two drugs. One targets and downregulates Trop-2 which is involved in CA-2+ signaling. Leronlomab downregulates CA-2+ itself.
The other drug is SN-38 that downregulates topoisomerase I. Topoisomerase I is implicated in tumor cellular repair. Leronlimab stops tumor cellular repair through the PI-3K/AKT pathway.
Now add leronlimab's other tumor fighting abilities - inhibits angiogenesis, anti-trafficking of tumor cells, increase in tumor fighting NKT cells, Stops the recruitment of Tregs to tumor sites (Tregs promote tumor immunity), downregulates IL-13 a tumor protectant, IL-4 (IL-4 promotes tumor immunity), upregulates IFN-gamma promoting tumor cell death and downregulates PD-L1.
(18)
(0)
